ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
The product is being launched in August 2023
Take proper precautions and seek timely treatment!
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety
Pfizer is likely to show GSK significant competition
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
Subscribe To Our Newsletter & Stay Updated
